XNYS
CVM
Market cap93mUSD
Oct 08, Last price
1.95USD
1D
-8.45%
1Q
41.30%
Jan 2017
-96.13%
Name
CEL-SCI Corp
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
27.05%
Rev. gr., 5y
-2.32%
Revenues
0
Net income
-25m
L-5.61%
CFO
-17m
L-8.99%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.
Key people
Geert R. Kersten
Chief Executive Officer, Treasurer, Director · since 1995
John Cipriano
Senior Vice President - Regulatory Affairs · since 2009
Daniel H. Zimmerman
Senior Vice President - Research, Cellular Immunology · since 2009
Eyal Talor
Chief Scientific Officer · since 2009
Patricia B. Prichep
Senior Vice President - Operations, Corporate Secretary · since 2000
Bruno Jean-Marie Baillavoine
Independent Director · since 2015
Robert Eugene Watson
Independent Director · since 2017
Peter R. Young
Independent Director · since 2002
Legal address
c/o C T CORPORATION SYSTEM
7700 E Arapahoe Rd
Ste 220
Centennial, CO 80112
US
7700 E Arapahoe Rd
Ste 220
Centennial, CO 80112
US
Headquarters
8229 Boone Blvd Ste 802
Vienna, VA 22182
US
Vienna, VA 22182
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑09 | 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑09 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||